Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
AIFF Catalyst Timeline
Dated clinical, regulatory and corporate events for Firefly Neuroscience, Inc.
Past FDA Catalysts and PDUFA Decisions
How AIFF actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Firefly Neuroscience, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every AIFF program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BMB-101 | neuropsychiatric disorders | Phase 1 | 2024-10-16 | positive topline findings from our recently completed Phase 1 study of BMB-101Read More | Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ TechnologyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DeCaprio DavidDirector, Officer (President and COO) | Acquisition | 44,872 77,866 held | $0.00 | 03/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AIFF
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in AIFF for Q3 2026. | ||||
Ownership Trends
AIFF Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How AIFF ranks across every disease it competes in
AIFF News
Firefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans as Commercial Expansion Accelerates
Firefly Neuroscience reported a 373% year-over-year increase in the utilization of its Evoke™ platform for ADHD scans in pediatric patients. This growth reflects expanding clinical adoption and revenue generation. The company is also leveraging a partnership with NeuroSigma to enhance its diagnostic-to-treatment model. Firefly's proprietary dataset now exceeds 200,000 EEG/ERP brain scans.
Read more →Firefly Neuroscience (NASDAQ: AIFF) Strengthens Non-Invasive Brain-Computer Interface Growth Strategy with Commercially Available Versus Platform
Firefly Neuroscience announced its Versus platform, which combines a wireless EEG headset with interactive software, enhancing non-invasive brain-computer interface (BCI) applications. The platform has shipped over 3,000 units and generates revenue while supporting Firefly's long-term growth strategy in the BCI and AI sectors. CEO Greg Lipschitz emphasized the potential for personalized training and broader applications.
Read more →Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD
Firefly Neuroscience and NeuroSigma have partnered to promote the Monarch eTNS® System, the first FDA-cleared non-drug treatment for pediatric ADHD. This collaboration aims to enhance clinician awareness and access to this innovative therapy through Firefly's Evoke™ platform, which offers objective assessments of brain function. The Monarch device is designed for children aged 7 to 12 who are not currently on ADHD medication.
Read more →Firefly Neuroscience’s Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial’s AI-Native Operating System for Brain Medicine
Firefly Neuroscience has partnered with Radial to integrate its Evoke™ EEG/ERP platform into Radial's AI-native operating system, RadialOS. This collaboration aims to enhance the diagnostic process in brain medicine by providing objective measures of brain function. The integration is expected to improve personalized treatment options and track patient outcomes effectively across Radial's extensive clinic network.
Read more →Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
Firefly Neuroscience reported a remarkable 291% increase in clinical assessments at TMS centers using its FDA-cleared Evoke™ platform. This AI-powered EEG/ERP system enhances the understanding of brain activity, enabling clinicians to tailor treatments for conditions like depression and anxiety. The CEO emphasized the importance of individualized treatment decisions based on objective brain data.
Read more →Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides
Firefly Neuroscience and Next Health have launched a precision cognitive health initiative following an FDA Advisory Committee's recommendation to ease restrictions on certain neuroprotective peptides. This collaboration aims to integrate AI-driven brain biomarker technology with personalized peptide protocols, potentially enhancing cognitive therapies. However, the recommendation is non-binding and further FDA actions are required for implementation.
Read more →Firefly’s AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD
Firefly Neuroscience has announced the discovery of a novel electrophysiological biomarker for PTSD using its FDA-cleared Evoke System. This breakthrough follows a partnership with the U.S. Department of War, aimed at improving assessments for military personnel suffering from PTSD. The discovery leverages advanced AI technology to analyze EEG data, potentially transforming diagnostic and treatment approaches for PTSD.
Read more →With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World’s First Known 200,000+ Standardized EEG/ERP Depository
Firefly Neuroscience has reached a significant milestone by surpassing 200,000 EEG/ERP brain scans, driven by a sequential growth of 5% to 17% over the past four quarters. This achievement supports their goal of creating the first EEG/ERP-based foundation model of the human brain, enhancing capabilities for cognitive biomarker discovery. The company aims to improve diagnostic methods for neurological disorders using advanced AI technologies.
Read more →Firefly Confirms Public-Private Partnership with the Department of War
Firefly Neuroscience has announced a partnership with the Department of War to utilize its FDA-cleared EEG/ERP technology for assessing and treating PTSD and TBI in U.S. service members. This collaboration aims to fill a gap in military mental health care by providing objective diagnostic tools. The partnership is expected to expand Firefly's presence in the government and defense health sectors.
Read more →Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD
Firefly Neuroscience has announced a significant advancement in identifying ADHD subtypes using AI-powered EEG technology. This breakthrough could enhance clinical diagnosis by providing objective biomarkers, potentially leading to more personalized treatment plans. The company aims to build the world's first EEG/ERP brain foundation model, leveraging a vast repository of brain scans to improve outcomes for ADHD patients.
Read more →Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration
Firefly Neuroscience, Inc. has reported significant growth, including a 20-fold expansion of its commercial footprint and a 33-fold increase in EEG/ERP brain scan volumes. The company has partnered with 99 commercial users, completing over 10,800 brain scans. Firefly aims to leverage AI and advanced GPU technology to enhance brain health outcomes and develop a foundation model of the human brain.
Read more →Firefly Neuroscience Reports Third Quarter 2025 Financial Results
Firefly Neuroscience reported third quarter revenue of $388,000, a thirty percent increase from the prior quarter. Total operating expenses fell to $2.8 million, down thirty five percent from the same period last year. The company recorded a net loss of $2.6 million, or $0.20 per share. This loss represents a thirty eight percent improvement compared to the $4.3 million loss in the previous year.
Read more →Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America
Firefly Neuroscience has partnered with HealingMaps to provide cognitive electrophysiology analytics to over 2,500 clinics across North America. This collaboration aims to enhance treatment outcomes for patients using ketamine, psilocybin, and TMS therapies by utilizing Firefly's FDA-cleared EEG-based analytics platform. The partnership is expected to empower clinics with objective data and new revenue opportunities.
Read more →Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform
Firefly Neuroscience has launched its new CLEAR Platform, utilizing NVIDIA's L40S GPU to enhance EEG data quality and processing speed. This innovative technology aims to improve brain health outcomes for patients with neurological disorders by enabling more accurate detection of neural biomarkers. The platform represents a significant advancement in clinical insights and supports Firefly's mission in neuroscience.
Read more →Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research
Firefly Neuroscience has entered a collaboration with Heidelberg University Hospital to study the neurophysiological effects of 15q13.3 copy number variants using its FDA-cleared BNA platform. The study will analyze EEG data from 30 subjects and aims to provide insights into cognitive disorders. This partnership underscores Firefly's commitment to advancing precision neuroscience and enhancing diagnostic methods.
Read more →Firefly Neuroscience to be Added to the Russell Microcap® Index
Firefly Neuroscience, an AI company focused on brain health, will join the Russell Microcap Index effective June 30, 2025. This inclusion marks a significant milestone for the company, reflecting its progress since its Nasdaq listing. CEO Greg Lipschitz highlighted recent achievements, including advancements in cognitive biomarkers and expansion of their technology platform. The membership is expected to enhance visibility among investors.
Read more →Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients
Firefly Neuroscience has made significant advancements in the objective measurement of subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia in Alzheimer's patients. Their study demonstrates that combining EEG/ERP and volumetric MRI can achieve up to 87% accuracy in diagnosing these conditions. This approach promises to enhance early detection and intervention, leveraging Firefly's proprietary technology and extensive database.
Read more →Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
Firefly Neuroscience has announced the acquisition of Evoke Neuroscience, significantly expanding its database, intellectual property portfolio, and commercial footprint. This acquisition is a strategic move to enhance Firefly's proprietary Brain Network Analytics technology, aimed at improving brain health outcomes. The deal is expected to facilitate rapid growth and innovation within the company.
Read more →Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
Firefly Neuroscience has acquired Evoke Neuroscience, enhancing its database and intellectual property portfolio. This acquisition is expected to significantly expand Firefly's capabilities in developing a foundation model of the human brain. The deal reflects a strategic move to leverage technological synergies and improve brain health outcomes for patients with neurological disorders.
Read more →Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million
Firefly Neuroscience has successfully exercised warrants, raising $8.8 million to support its initiatives. The funds will be allocated towards the development of its FDA-cleared Brain Network Analytics technology, aimed at improving brain health outcomes. The company expresses gratitude towards shareholders for their confidence, highlighting a robust cash position extending into mid-2026.
Read more →